Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial (Q35998447)

11 August 2017

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial (English)

1 reference

11 August 2017

phase I clinical trial

0 references

1 reference

C Dive

10

0 references

author name string

J Cummings

1

1 reference

11 August 2017

M Zweifel

2

1 reference

11 August 2017

N Smith

3

1 reference

11 August 2017

P Ross

4

1 reference

11 August 2017

J Peters

5

1 reference

11 August 2017

G Rustin

6

1 reference

11 August 2017

P Price

7

1 reference

11 August 2017

M R Middleton

8

1 reference

11 August 2017

T Ward

9

1 reference

11 August 2017

language of work or name

English

0 references

publication date

26 April 2012

1 reference

British Journal of Cancer

11 August 2017

1 reference

11 August 2017

106

1 reference

11 August 2017

11

1 reference

11 August 2017

1766-1771

1 reference

Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Fit-for-purpose biomarker method validation in anticancer drug development

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Utilization of cytokeratin-based biomarkers for pharmacodynamic studies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Cytokeratin 18 in plasma of patients with gastrointestinal adenocarcinoma as a biomarker of tumour response

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Measuring soluble forms of extracellular cytokeratin 18 identifies both apoptotic and necrotic mechanisms of cell death produced by adenoviral-mediated interferon alpha: possible use as a surrogate marker

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Keratin 8/18 breakdown and reorganization during apoptosis.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

A novel high-through-put assay for screening of pro-apoptotic drugs

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Specificity and accuracy data for ligand-binding assays for macromolecules should be interpreted with caution

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

The levels of caspase-cleaved cytokeratin 18 are elevated in serum from patients with lung cancer and helpful to predict the survival

11 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3364117

Preclinical evaluation of vascular-disrupting agents in Ewing's sarcoma family of tumours

11 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Optimisation of circulating biomarkers of cell death for routine clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Apoptosis generates stable fragments of human type I keratins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Cytokeratins 8 and 18 in adult human corneal endothelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Elevated serum levels of M30 and M65 in patients with locally advanced head and neck tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Induction of rapid and reversible cytokeratin filament network remodeling by inhibition of tyrosine phosphatases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Diagnostic and prognostic role of plasma levels of two forms of cytokeratin 18 in patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.165

Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis

21 January 2018

1 reference

12 December 2020

An immunohistochemical study of the clearance of apoptotic cellular fragments

1 reference

12 December 2020

[Immunohistochemistry of cytokeratin expression in human blood vessel endothelia with special reference to synovial connective tissue]

1 reference

12 December 2020

Circulating endothelial cells, von Willebrand factor, interleukin-6, and prognosis in patients with acute coronary syndromes

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.2012.165

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

22538971

1 reference